Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02472418 · ClinicalTrials.gov registry record · Phase 2

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

A Phase 2 study, sponsored by Dr. Reddy's Laboratories Limited.

Completed
Registry status
Phase 2
Development phase
63
Enrollment target

NCT02472418: Completed Phase 2 study, sponsored by Dr. Reddy's Laboratories Limited.

NCT02472418 is a Phase 2 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02472418, a Phase 2 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.

COMPLETED
Registry status
Phase 2
Development phase
63 participants
Enrollment target

Study Summary

Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.

Primary Outcome

Percentage of subjects who are migraine headache free at 2 hours after taking study drug administration

Interventions

  • DRUG DFN-15 Dose A (treatment A)
  • DRUG DFN-15 Dose B (treatment B)
  • OTHER Placebo (treatment C)

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2015-06-05
Est. Completion 2016-05-05
Phase Phase 2
Dr. Reddy's Laboratories Limited

52 total trials

What the finished NCT02472418 record still lists

NCT02472418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 3 interventions - of which DFN-15 Dose A (treatment A) is the first listed.

NCT02472418 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02472418 about?

NCT02472418 is a clinical study titled "Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches". Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.

What is the current status of trial NCT02472418?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2015-06-05. Estimated completion is 2016-05-05.

What interventions are being tested in trial NCT02472418?

The interventions under investigation include: DFN-15 Dose A (treatment A) (DRUG), DFN-15 Dose B (treatment B) (DRUG), Placebo (treatment C) (OTHER).

Who is sponsoring clinical trial NCT02472418?

This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02472418's enrollment target sits among peer trials

63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02472418, the US trial registry maintained by the National Library of Medicine. NCT02472418 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.